You just read:

UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.

News provided by

UCB

May 29, 2018, 08:00 ET